Centrum Broking has buy call on with a target price of Rs 21225. The current market price of Abbott India Ltd. is Rs 16626.9. Time period given by analyst is one year when Abbott India Ltd. price can reach defined target.
Abbott India Ltd., incorporated in the year 1944, is a Large Cap company (having a market cap of Rs 35259.71 Crore) operating in Pharmaceuticals sector.
Financials
For the quarter ended 31-03-2021, the company reported a Standalone Total Income of Rs 1111.74 Crore, up .12 % from last quarter Total Income of Rs 1110.38 Crore and up 12.37 % from last year same quarter Total Income of Rs 989.33 Crore. Company reported net profit after tax of Rs 152.47 Crore in latest quarter.
Investment Rationale
The core leading brands of BOOT have been sustaining high double digits’ growth which the brokerage expects would sustain and improve post the pandemic environment. It expects BOOT to sustain delivering market beating growth 2-3% ahead of IPM, including the new launches support. A focused drive to improve the operational efficiencies, cost reduction and positive product mix would result in margin improvement. It values AIL at 41x FY23E EPS. It maintains BUY rating and TP of Rs 21,225. At CMP of Rs 16,873, the stock trades at 37.9x FY22E EPS of Rs 443.8 and 32.7x FY23E EPS of Rs 516.5. Key risks to call includes domestic growth risk and any additional brand coming under price control.
Promoter/FII Holdings
Promoters held 75 per cent stake in the company as of March 31, 2021, while FIIs held 1.9 per cent, DIIs 4.6 per cent and public and others 18.5 per cent.
Abbott India Ltd., incorporated in the year 1944, is a Large Cap company (having a market cap of Rs 35259.71 Crore) operating in Pharmaceuticals sector.
Financials
For the quarter ended 31-03-2021, the company reported a Standalone Total Income of Rs 1111.74 Crore, up .12 % from last quarter Total Income of Rs 1110.38 Crore and up 12.37 % from last year same quarter Total Income of Rs 989.33 Crore. Company reported net profit after tax of Rs 152.47 Crore in latest quarter.
Did you Know?
Stock score of Abbott India Ltd moved up by 1 in 3 months on a 10-point scale.
View Latest Stock Report »Investment Rationale
The core leading brands of BOOT have been sustaining high double digits’ growth which the brokerage expects would sustain and improve post the pandemic environment. It expects BOOT to sustain delivering market beating growth 2-3% ahead of IPM, including the new launches support. A focused drive to improve the operational efficiencies, cost reduction and positive product mix would result in margin improvement. It values AIL at 41x FY23E EPS. It maintains BUY rating and TP of Rs 21,225. At CMP of Rs 16,873, the stock trades at 37.9x FY22E EPS of Rs 443.8 and 32.7x FY23E EPS of Rs 516.5. Key risks to call includes domestic growth risk and any additional brand coming under price control.
Promoter/FII Holdings
Promoters held 75 per cent stake in the company as of March 31, 2021, while FIIs held 1.9 per cent, DIIs 4.6 per cent and public and others 18.5 per cent.
(Disclaimer: Views and recommendations given in this section are the analysts' own and do not represent those of ETMarkets.com. Please consult your financial adviser before taking any position in the stock/s mentioned.
Read More News on
Download The Economic Times News App to get Daily Market Updates & Live Business News.
